You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 31, 2025

Claims for Patent: 9,931,402

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,931,402

Title:	Compositions for the treatment of solid tumors
Abstract:	The present invention relates to a pharmaceutical combination that comprises an IGF1R inhibitor and an mTOR inhibitor for the treatment of cancer in a subject; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of medicament for the treatment of cancer; a kit comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and a method of treating cancer in a subject, especially a human.
Inventor(s):	Hurwitz; Herbert I. (Durham, NC), Vlahovic; Gordana (Durham, NC)
Assignee:	Duke University (Durham, NC)
Application Number:	15/586,727
Patent Claims:	1. A pharmaceutical composition comprising an IGF1R inhibitor and an mTOR inhibitor in a pharmaceutically acceptable carrier, wherein the IGF1R inhibitor is ganitumab and the mTOR inhibitor is everolimus. 2. The composition of claim 1, wherein the composition comprises ganitumab is in an amount of about 0.05 mg to about 5 g. 3. The composition of claim 1, wherein the composition comprises ganitumab is in an amount of about 0.5 mg to about 5 g. 4. The composition of claim 1, wherein the composition comprises ganitumab is in an amount of about 1 mg to about 2 g. 5. The composition of claim 1, wherein the composition comprises everolimus in an amount of about 0.1 mg to about 10 mg. 6. The composition of claim 1, wherein the composition comprises everolimus in an amount of about 2 mg to about 8 mg. 7. The composition of claim 1, wherein the composition comprises everolimus in an amount of about 5 mg. 8. A kit comprising an IGF1R inhibitor and an mTOR inhibitor, wherein the IGF1R inhibitor is ganitumab and the mTOR inhibitor is everolimus, and printed instructions directing the use of a combined treatment of ganitumab and everolimus for treating cancer in a subject. 9. The kit of claim 8, wherein the ganitumab and the everolimus are in separate containers. 10. The kit of claim 9, wherein the ganitumab and the everolimus are in separate containers. 11. The kit of claim 8, wherein the ganitumab and the everolimus are in a unit dosage form. 12. The kit of claim 11, herein the ganitumab and the everolimus are in the same containers. 13. The kit of claim 8, further comprising a sterile diluent.

Details for Patent 9,931,402

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biosolutions Canada Inc.	ACCRETROPIN	somatropin	Injection	021538	January 23, 2008	9,931,402	2037-05-04
Merck Sharp & Dohme Llc	ZOSTAVAX	zoster vaccine live	For Injection	125123	May 25, 2006	9,931,402	2037-05-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 9,931,402

Subscribe to access the full database, or Get Started Free
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2013071056	⤷ Get Started Free
United States of America	9700619	⤷ Get Started Free
United States of America	2017239352	⤷ Get Started Free
United States of America	2015044223	⤷ Get Started Free
Japan	6268097	⤷ Get Started Free
Japan	2014533277	⤷ Get Started Free
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.